Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026
Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Drug

Vcanbio’s Stem Cell Therapy VUM02 Gets NMPA Approval for Systemic Sclerosis Clinical Trial

Fineline Cube Sep 10, 2024

Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), a biotechnology company based in China,...

Company Deals

Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation

Fineline Cube Sep 10, 2024

Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...

Policy / Regulatory

NHC Releases Updated List of Pediatric Drugs for Research and Development Incentives

Fineline Cube Sep 10, 2024

The National Health Commission (NHC) has issued a notification regarding the fifth batch of pediatric...

Company Drug

Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial

Fineline Cube Sep 10, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Drug Policy / Regulatory

China’s CDE Issues Draft Guidelines for Biosimilar Pharmaceutical Similarity Research

Fineline Cube Sep 10, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...

Company Deals R&D

Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation

Fineline Cube Sep 9, 2024

Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...

Policy / Regulatory

China’s 2024 Negative List Eases Restrictions on Foreign Investment in TCM and Biotechnology

Fineline Cube Sep 9, 2024

The National Development and Reform Commission (NDRC) of China has announced the release of the...

Policy / Regulatory

China’s NMPA Proposes Inclusion of Cochlear Implants in Volume-Based Procurement Plans

Fineline Cube Sep 9, 2024

The National Medical Products Administration (NMPA) has disclosed plans to expand the scope of its...

Company Deals Medical Device

Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs

Fineline Cube Sep 9, 2024

Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell...

Company Drug

Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study

Fineline Cube Sep 9, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Policy / Regulatory

China’s NHSA Proposes New Guidelines to Enhance Oversight of Medical Insurance Funds

Fineline Cube Sep 9, 2024

The National Healthcare Security Administration (NHSA) has unveiled a draft of the “Guiding Opinions on...

Company Deals

Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership

Fineline Cube Sep 9, 2024

Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray...

Policy / Regulatory

China Opens Doors to Foreign Biotech and Wholly-Owned Hospitals in Healthcare Sector Expansion

Fineline Cube Sep 9, 2024

China’s Ministry of Commerce, National Health Commission, and National Medical Products Administration (NMPA) have jointly...

Company

Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce

Fineline Cube Sep 9, 2024

Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...

Policy / Regulatory

Guangzhou Health Commission Unveils Ten Measures to Boost Innovative Pharma and Medical Device Development

Fineline Cube Sep 9, 2024

On September 5, 2024, the Guangzhou Health Commission issued the “Guangzhou Health Commission’s Ten Measures...

Company Drug

Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial

Fineline Cube Sep 9, 2024

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its...

Company Policy / Regulatory

Biosecure Act Faces Opposition from Senior House Democrat Jim McGovern

Fineline Cube Sep 9, 2024

The trajectory of the US Biosecure Act through the House of Representatives encountered unexpected turbulence...

Company Drug Policy / Regulatory

China’s CDE Releases 86th Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Sep 9, 2024

China’s Center for Drug Evaluation (CDE) has unveiled its 86th roster of reference preparations for...

Company Drug

Akeso’s Ivonescimab Shows Promising Results in Phase III Clinical Trial for Hepatocellular Carcinoma

Fineline Cube Sep 9, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced that its first-in-class...

Company Legal / IP

AstraZeneca Faces Investigation in China Over Data Privacy and Unapproved Drugs

Fineline Cube Sep 6, 2024

AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, is reportedly under the spotlight in Shenzhen,...

Posts pagination

1 … 247 248 249 … 613

Recent updates

  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
  • Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.